10,768 Shares in CVS Health Corporation $CVS Acquired by Hanseatic Management Services Inc.

Hanseatic Management Services Inc. acquired a new stake in shares of CVS Health Corporation (NYSE:CVS) in the first quarter, HoldingsChannel reports. The institutional investor acquired 10,768 shares of the pharmacy operator’s stock, valued at approximately $773,000.

Other large investors have also added to or reduced their stakes in the company. Caitong International Asset Management Co. Ltd grew its stake in shares of CVS Health by 407.2% in the third quarter. Caitong International Asset Management Co. Ltd now owns 350 shares of the pharmacy operator’s stock worth $26,000 after acquiring an additional 281 shares during the last quarter. Swiss RE Ltd. bought a new position in shares of CVS Health during the fourth quarter valued at $26,000. Sankala Group LLC purchased a new position in shares of CVS Health in the 4th quarter worth about $28,000. Global Trust Asset Management LLC boosted its stake in CVS Health by 344.8% in the 1st quarter. Global Trust Asset Management LLC now owns 387 shares of the pharmacy operator’s stock worth $28,000 after purchasing an additional 300 shares in the last quarter. Finally, Mcguire Capital Advisors Inc. bought a new position in CVS Health in the 4th quarter worth about $28,000. Hedge funds and other institutional investors own 80.66% of the company’s stock.

Insiders Place Their Bets

In other CVS Health news, Director Larry Robbins sold 370,462 shares of the firm’s stock in a transaction dated Thursday, May 21st. The stock was sold at an average price of $93.45, for a total value of $34,619,673.90. Following the transaction, the director directly owned 4,824,799 shares of the company’s stock, valued at approximately $450,877,466.55. This trade represents a 7.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Tilak Mandadi sold 69,551 shares of the stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total transaction of $6,230,378.58. Following the completion of the transaction, the executive vice president owned 10,133 shares in the company, valued at $907,714.14. This trade represents a 87.28% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders have sold 3,441,551 shares of company stock valued at $323,703,977. Company insiders own 0.85% of the company’s stock.

Key Stories Impacting CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: CVS opened its first pharmacy-focused location in Houston and plans to roll out nearly 20 similar sites, signaling an effort to expand access to in-person pharmacy care and strengthen its retail footprint. CVS Pharmacy® celebrates opening of first pharmacy-focused location in Houston
• Positive Sentiment: Management reiterated a constructive stance on GLP-1 drugs and pharmacy economics, with CEO comments highlighting that insurers may eventually cover weight-loss drugs more broadly once prices fall, reinforcing CVS’s role in cost management and pharmacy benefit services. CVS Health CEO David Joyner warns private insurers won’t cover GLP-1s for weight loss until drug prices drop
• Positive Sentiment: CVS also floated cost-saving solutions and a settlement in Georgia that could reduce prescription costs for some patients, which may improve public perception and support demand for its pharmacy services. New CVS settlement could lower prescription costs for some Georgians
• Neutral Sentiment: Coverage around CVS education benefits and talent development highlights workforce stability, but it is unlikely to have an immediate impact on the stock. At CVS, education benefits strengthen talent pipelines
• Neutral Sentiment: Broader analyst and media discussion of CVS’s dividend and GLP-1 strategy has helped reinforce the investment case, but this appears more supportive than a near-term catalyst. How Investors May Respond To CVS (CVS) Dividend Move And GLP?1 Strategy Across Its Health Platform

Wall Street Analysts Forecast Growth

CVS has been the subject of a number of analyst reports. Cantor Fitzgerald raised their price objective on shares of CVS Health from $100.00 to $110.00 and gave the company an “overweight” rating in a research note on Tuesday, July 7th. TD Cowen upped their target price on shares of CVS Health from $105.00 to $110.00 and gave the stock a “buy” rating in a research note on Monday, May 11th. Argus raised their price target on shares of CVS Health from $90.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, May 14th. UBS Group boosted their price objective on shares of CVS Health from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Monday, June 8th. Finally, HSBC reaffirmed a “hold” rating and issued a $103.00 price objective on shares of CVS Health in a research report on Monday, July 6th. Twenty-one investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $105.38.

CVS Health Price Performance

Shares of NYSE:CVS opened at $107.36 on Friday. The business has a 50-day simple moving average of $98.97 and a two-hundred day simple moving average of $85.13. The company has a debt-to-equity ratio of 0.78, a quick ratio of 0.66 and a current ratio of 0.87. The firm has a market cap of $136.99 billion, a price-to-earnings ratio of 47.30, a price-to-earnings-growth ratio of 1.05 and a beta of 0.61. CVS Health Corporation has a fifty-two week low of $58.50 and a fifty-two week high of $108.97.

CVS Health (NYSE:CVS) last announced its quarterly earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a net margin of 0.72% and a return on equity of 11.88%. The firm had revenue of $100.43 billion during the quarter, compared to analyst estimates of $94.99 billion. During the same period in the previous year, the business posted $2.25 earnings per share. The business’s revenue for the quarter was up 6.2% on a year-over-year basis. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. On average, analysts expect that CVS Health Corporation will post 7.46 earnings per share for the current year.

CVS Health Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd will be given a $0.665 dividend. This represents a $2.66 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date of this dividend is Thursday, July 23rd. CVS Health’s payout ratio is 117.18%.

CVS Health Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over?the?counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in?store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk?in medical clinics and HealthHUB locations that offer expanded clinical services.